The treatment of glioblastomas: A systematic update on clinical Phase III trials

Yin, Anan; Cheng, Jinxiang; Zhang, Xiang; Liu, Bo-lin

doi:10.1016/j.critrevonc.2013.01.007

Cited by 32 publications

(32 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Especially during treatment, mentioning poor prognosis and approaching death was reported to be difficult, in the present study and in previous ones [32,33]. Because there is no convincing evidence that life expectancy will be prolonged substantially by second-line treatment for patients with recurrent glioblastoma, it is highly important to communicate this information [9,17,21,25,26]. If patients know that they may eventually benefit from treatment for only a few months, the decision not to start treatment may become more attractive.…”

Section: Equipoisementioning

confidence: 95%

“…Furthermore, the decision to start chemotherapy is not always based on scientific evidence [9,12,16].This raises doubts about how the decisions concerning subsequent lines of chemotherapy are made. Little attention has been paid to the perspectives of medical specialists on chemotherapy in the last phase of life and shared decision making.…”

Section: Introductionmentioning

confidence: 99%

“…Although first-line therapy is shown to be successful in life prolongation, second-line chemotherapy seems to be less effective in prolonging life [7][8][9]. Some studies show that after second-line therapy, approximately 20% of the patients are progression-free after 6 months [9][10][11]. Because chemotherapy may involve harmful side effects, its administration might result in serious discomfort for advanced cancer patients in their last phase of life [12].…”

Section: Introductionmentioning

confidence: 99%

“…This is the case in advanced cancer care, in which patients and physicians are faced with the question of whether to start advanced lines of noncurative chemotherapy. Although first-line therapy is shown to be successful in life prolongation, second-line chemotherapy seems to be less effective in prolonging life [7][8][9]. Some studies show that after second-line therapy, approximately 20% of the patients are progression-free after 6 months [9][10][11].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Perspectives of Medical Specialists on Sharing Decisions in Cancer Care: A Qualitative Study Concerning Chemotherapy Decisions With Patients With Recurrent Glioblastoma

et al. 2015

View full text Add to dashboard Cite

Background. In cancer care, difficult decisions concerning advanced treatment need to be made, weighing possible life prolongation against harmful side effects. Treatment is frequently started, showing the need to explore how decisions are made. Little is known about the perspectives of physicians on sharing decision making with patients.This qualitative study aimed to describe the perspectives of medical specialists on the decision-making process with patients with glioblastoma concerning starting new treatment. Methods. Qualitative interviews were held with medical specialists. One focus group was organized with medical professionals. Their opinions about elements of shared decision making and the applicability in the context of patients with glioblastoma were assessed. The topic list for the focus group was based on the analysis of the interviews. Qualitative analysis of the transcripts was performed by three researchers independently.

show abstract

Section: Equipoisementioning

confidence: 95%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Perspectives of Medical Specialists on Sharing Decisions in Cancer Care: A Qualitative Study Concerning Chemotherapy Decisions With Patients With Recurrent Glioblastoma

et al. 2015

View full text Add to dashboard Cite

show abstract

“…In spite of diagnostics and treatment improvement, the MG mortality rate is still high, and the treatment outcomes are unsatisfactory. With modern standards of medical services, the median survival for patients with the most malignant glioma (G4) is 12-15 months, despite intensive multimodal therapy [2].…”

Section: Introductionmentioning

confidence: 99%

Concurrent thermochemoradiotherapy for brain high-grade glioma

Ryabova¹,

Novikov²,

Чойнзонов³

et al. 2016

AIP Conference Proceedings

View full text Add to dashboard Cite

Abstract. Despite the achievements in the current strategies for treatment, the prognosis in malignant glioma patients remains unsatisfactory. Hyperthermia is currently considered to be the most effective and universal modifier of radiotherapy and chemotherapy. Preliminary treatment outcomes for 28 patients with newly diagnosed (23) and recurrent (5) high-grade gliomas were presented. All the patients received multimodality treatment including surgery, thermochemoradiotherapy followed by 4 cycles of adjuvant chemotherapy. All the patients endured thermochemoradiotherapy well.

show abstract

miR‐222/GAS5 is involved in DNA damage and cytotoxic effects induced by temozolomide in T98G cell line

Huang

Jiang

Lian

et al. 2018

J of Applied Toxicology

View full text Add to dashboard Cite

Temozolomide (TMZ), a therapeutic DNA alkylator that can cause lethal DNA damage in cancer cells, is widely used for the standard chemotherapy against glioblastoma. However, long‐term treatment with TMZ often causes drug resistance and poor prognosis, the mechanism of which remains largely unclear. This study aimed to investigate the possible role of miR‐222/GAS5 axis on DNA damage and cytotoxic effects induced by TMZ in glioblastoma cells (T98G). Data suggest that the DNA comet tail length of T98G is positively correlated with the levels of miR‐222 (R2 = 0.9808, P < 0.05), and negatively correlated with the levels of GAS5 (R2 = 0.8903, P < 0.05). The optical density value of T98G is negatively correlated with the levels of miR‐222 (R2 = 0.7848, P < 0.05), and positively correlated with the levels of GAS5 (R2 = 0.6886, P < 0.05). Furthermore, comet tail length and optical density value are negatively and positively correlated with the levels of O‐6‐methylguanine‐DNA methyltransferase, respectively (R2 = 0.8462, P < 0.05; R2 = 0.7018, P < 0.05). In conclusion, miR‐222/GAS5 is involved in DNA damage and cytotoxic effects induced by TMZ, which means that miR‐222/GAS5 may have great potential of being used as a biomarker for screening of chemotherapeutic alkylators.

show abstract

The treatment of glioblastomas: A systematic update on clinical Phase III trials

Cited by 32 publications

References 81 publications

Perspectives of Medical Specialists on Sharing Decisions in Cancer Care: A Qualitative Study Concerning Chemotherapy Decisions With Patients With Recurrent Glioblastoma

Perspectives of Medical Specialists on Sharing Decisions in Cancer Care: A Qualitative Study Concerning Chemotherapy Decisions With Patients With Recurrent Glioblastoma

Concurrent thermochemoradiotherapy for brain high-grade glioma

miR‐222/GAS5 is involved in DNA damage and cytotoxic effects induced by temozolomide in T98G cell line

Contact Info

Product

Resources

About